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Edited by Maurice MontalAbstract The purpose of this study was to identify Cl channels
in the basolateral membrane of airway epithelial cells at the
molecular level. We have focused on a new family of Cl
channels, bestrophins, which have previously been identiﬁed in
retinal pigment epithelium. RT-PCR, Western blot and confocal
microscopy studies revealed the presence of bestrophin in airway
epithelial cells. Decreasing bestrophin expression using siRNA
resulted in diminished 36Cl ﬂux. These studies also showed that
bestrophin regulation is similar to that of native basolateral Cl
channels. The data indicate that the presence of a functional
bestrophin may contribute to the basolateral cell conductance in
airway epithelial cells.
 2004 Published by Elsevier B.V. on behalf of the Federation of
European Biochemical Societies.
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cGMP1. Introduction
The presence of Cl channels in the basolateral membrane
of airway epithelial cells has been established in several studies
[1–4], but their physiological role is not well characterized. In a
search for the molecular identity of the basolateral Cl chan-
nels, we have considered the members of the well established
(CLC, CFTR, and GABA/glycine receptors), and less well-
characterized (CLIC or CLCA) Cl channel families as pos-
sible candidates (for review see [5]). Among these, ClC-2
channels have been localized to the basolateral membrane in
diﬀerent cell types [6–8], but these channels are unlikely to play
a major role in human airway epithelia because basolateral Cl
channels are regulated via cAMP-dependent pathways [3,9],
while ClC-2 channels are not [5].
Recently, a new family of putative Cl channels, bestro-
phins, has been identiﬁed in retinal pigment epithelium (RPE)
[10]. Bestrophin is a protein encoded by the vitelliform macular
dystrophy type 2 (VMD2) gene [11,12], which is mutated in
Best macular dystrophy [13]. It localizes to the basolateral
membrane of RPE cells [14] and constitutes a new family of
Cl channels unrelated in primary sequence to any previously
characterized channel proteins [15–17].
In this study, we have investigated bestrophin expression in
Calu-3 cells, an airway serous cell model [18], and used a small
interfering RNA (siRNA) approach to transiently and specif-
ically reduce its expression. Our ﬁndings indicate that bestro-* Corresponding author. Fax: +1-780-492-8915.
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expression results in diminished apical-to-basolateral 36Cl
ﬂux.2. Materials and methods
2.1. Cell culture
Calu-3 cells were grown as previously described [9]. For transepi-
thelial measurements, cells were seeded onto Costar Snapwell inserts
(0.45-lm pore size) and grown submerged in culture medium for the
ﬁrst 6 days. Subsequently, air interface culturing was used, in which the
medium was added only to the basolateral side of the inserts. Inserts
were used for experiments 10–16 days after the establishment of an air
interface.
2.2. RT-PCR
Forward and reverse primers for bestrophin (VMD2, GenBankTM
Accession No. NM_0004183) were nucleotides 329–348 and 516–535,
respectively. As a positive control, plasmid containing VMD2 gene (a
generous gift from Dr. I. McDonald, Ophthalmology, University of
Alberta) was used. DNA ampliﬁcation was obtained by annealing for 1
min at 58 C, followed by an elongation step at 72 C for 1 min. The
size of the ampliﬁed product was 207 bp and was sequenced by the
University of Alberta DNA Sequencing Core Facility to conﬁrm its
identity.
2.3. Immunocytochemistry
Western blotting was performed as described elsewhere [19]. Primary
rabbit polyclonal antibody against bestrophin (Bst-101AP) was
purchased from FabGennix Inc., Shreveport, LA. Where appropriate,
pre-absorption controls were carried out, using the blocking peptide
supplied with the antibody. Controls were also carried out in which the
primary antibody was replaced with PBS; these were negative (not
shown). A minimum of three runs was carried out and a representative
example is shown. Optical band densities were determined using Sigma
Gel software (Jandel Scientiﬁc).
2.4. Transepithelial measurements
Ussing chamber studies were performed as previously described [20].
Cells grown on inserts were mounted into CHM5 Ussing chambers
(WPI, Sarasota, Fl), and bathed on apical and basolateral sides with 10
ml of Krebs Henseleit Solution (KHS) containing (mM): 116 NaCl, 4.7
KCl, 2.5 CaCl2, 1.2 MgCl2, 25 NaHCO3, 1.2 KH2PO4, and 11.1
glucose, pH 7.4 [9]. Solutions were warmed to 37 C and circulated
with a gas lift using 95% O2–5% CO2. During all experiments, the Isc
was allowed to stabilize for 20 min prior to treatments. In all experi-
ments, amiloride (10 lM, apical) was present in the apical compart-
ment to inhibit ENaC-mediated Naþ absorption. Stock solutions for
4,40-diisothiocyanatostilbene-2,20-disulfonic acid (DIDS, 5 mM), S-
nitroso-glutathione (GSNO, 100 mM) and amiloride (10 mM) were
prepared in H2O, whereas forskolin (10 mM) was prepared in ethanol.
All chemicals were from Sigma (St. Louis, MO).
2.5. RNA interference
The selection of the coding sequence for siRNA was determined
using Qiagen siRNA Designer (Qiagen, Mississauga, Ont., Canada)
and was analyzed by BLAST research to ensure that it did not haveation of European Biochemical Societies.
Fig. 1. Expression of bestrophin in Calu-3 cells. Calu-3 mRNA was
reverse-transcribed into cDNA and PCR-ampliﬁed using bestrophin-
speciﬁc primers (lane 1 from left). GAPDH ampliﬁcation of the same
sample is shown as a control for RNA quality. Plasmid containing
VMD2 gene was used as a positive control. PCR ampliﬁcation was
also conducted on RNA preparations (without reverse transcription)
to control for possible genomic contamination (lane 4). The expected
sizes of the PCR products are 207 bp (bestrophin) and 595 bp
(GAPDH). Marker-DNA standard (a 100-bp ladder).
Fig. 2. Speciﬁc knockdown of bestrophin expression in Calu-3 cells by
siRNA. Cells, cultured on 6-well plates, were subjected to transfection
with either bestrophin siRNA or control siRNA. At 72 h post-trans-
fection, cells were homogenized and representative samples were as-
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tides purchased as ready-annealed puriﬁed duplexes from Qiagen
(sense 50-CACAAGCAGUUGGAGAAACdTdT-30, antisense 30-
dTdTGUGUUCGUCAACCUCUUUG-50) targeted bestrophin
mRNA sequence in positions 588–608. Transfection was carried out
using Qiagen RNAi Starter Kit. Control siRNA was ﬂuorescein-la-
beled, 21 bp of random sequences provided by Qiagen, and were also
used to optimize transfection eﬃciency. In preliminary studies, we
found that the 1:9 (lg:ll) ratio of RNAiFect Transfection Reagent to
siRNA, produced the best results, with over 80% of cells being
transfected. The experiments were performed with cells grown to
conﬂuency at the air–liquid interface. 14.5 ll of 20 lM siRNA and
33.75 ll of transfection reagent were added to a medium in a total
volume of 250 ll, and left for 15 min at room temperature to allow
formation of transfection complexes. Subsequently, the mixture was
diluted with a complete cell culture medium to a total volume of 1 ml,
added to the basolateral side, and the cells were incubated for 72 h.
2.6. Radioisotopic ﬂux
Calu-3 inserts were short-circuited for 20 min prior to the addition of
the radioisotope. At time zero (T0), background samples were taken,
followed by the addition of 3 lCi of 36Cl (speciﬁc activity of 0.126
mCi/ml, Amersham Pharmacia Biotech, UK) to the basolateral com-
partment,and another 20 min allowed for the establishment of equi-
librium. At this time (T20), 0.5 ml of samples was taken from the apical
side and replaced with fresh KHS; this was repeated at 10 min. in-
tervals thereafter. Three samples were taken (T20–T40) before the ad-
dition of forskolin (10 lM); this was followed by two more samples
taken (T50 and T60) before the addition of basolateral DIDS (50 lM)
and a further two samples taken (T70 and T80) after DIDS treatment.
Two samples were also taken from the basolateral side before treat-
ment with forskolin, to calculate the speciﬁc activity. Samples were
counted in a liquid scintillation counter and the basolateral-to-apical
ﬂux ðJClBAÞ was calculated according to standard equations [21]. 36Cl
ﬂuxesin the apical-to-basolateral ðJClABÞ direction were measured in
exactly the same fashion, except that the radioisotope was added to the
apical bathing solution. Net 36Cl ﬂux ðJClnetÞ was calculated as
JClnet ¼ JClBA  JClAB.
2.7. Statistical analysis
Results are presented as means S.E.; n refers to the number of
experiments. The paired Student’s t test was used to compare the
means of two groups. Diﬀerences among the means of multiple groups
were determined by one-way analysis of variance with the Tukey–
Kramer post-test using Instat 3.05 (Graphpad software, San Diego,
CA).sayed by Western blotting. The blot shown is representative of three
experiments and actin served as a loading control. The bestrophin
antibody labels a 68-kDa protein in Calu-3 cells.3. Results
Fig. 1 shows that Calu-3 cells express bestrophin mRNA
under normal cell culture conditions. To estimate the possible
sensitivity of Calu-3 cells to bestrophin knockdown by siRNA,
initial experiments were performed at 24 h post-transfection.
No signiﬁcant diﬀerences were revealed between control cells
and cells transfected with bestrophin siRNA (data not shown).
However, 72 h incubation with bestrophin-directed siRNA
resulted in signiﬁcant and speciﬁc suppression of bestrophin
protein, as judged by Western blotting (Fig. 2). Measurement
of band optical density indicated that the siRNA treatment
reduced the bestrophin band intensity to 34.6 5.8% (n ¼ 3) of
its control value.
The next set of experiments studied Isc in Calu-3 monolayers
transfected with either bestrophin siRNA or with control
siRNA (Fig. 3). The average transepithelial resistance and
baseline Isc in bestrophin siRNA treated cell inserts were
356.5 40 X cm2 and 30.9 2.7 lA cm2 (n ¼ 6), respectively,
and were not diﬀerent from control values (287.0 24.5 X cm2
and 41.6 7.3 lA cm2 (n ¼ 6), respectively). Similarly, the
eﬀects of the nitric oxide donor, GSNO (100 lM), on the peakIsc were not signiﬁcantly diﬀerent in control and siRNA treated
cells (41.1 10.3 lA cm2, n ¼ 3 and 46.6 6.6 lA cm2, n ¼ 6,
respectively). However, subsequent application of DIDS (50
lM, basolateral) increased Isc by 25.6 3.5 lA cm2 (n ¼ 3)
under control conditions, but only by 7.4 1.1 lA cm2 (n ¼ 6,
P < 0:01) after siRNA treatment. These results suggest that
bestrophin siRNA aﬀects the function of basolateral DIDS-
sensitive Cl channels.
A direct way to show that bestrophin siRNA treatment af-
fects chloride secretion is to measure chloride movement using
36Cl. Unidirectional 36Cl ﬂuxes were measured in both the
basolateral to apical (JBA) and in the apical to basolateral (JAB)
directions. Fig. 4 shows the net 36Cl ﬂux rate ðJClnetÞ during
each sample interval in control and siRNA-treated cells. This
information is supplemented with unilateral 36Cl ﬂux data in
Table 1. Consistent with the ﬁndings from earlier studies [9,22],
the data conﬁrm that under basal conditions there is no net
movement of 36Cl in Calu-3 cells. Interestingly, cells treated
with bestrophin siRNA showed higher baseline and forskolin
Fig. 3. Bestrophin siRNA reduces DIDS-sensitive basolateral Cl conductance in Calu-3 cells. Representative recordings (siRNA-treated, n ¼ 6;
control, n ¼ 3) show Isc responses to GSNO (100 lM, bilateral) and DIDS (50 lM, basolateral). The eﬀect of DIDS on GSNO-activated Isc is
reduced by more than 70% (from 14.8 1.3 to 4.2 0.8 lA/cm2, n ¼ 6) in bestrophin vs. control siRNA treated cells.
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Fig. 4. Net 36Cl ﬂuxes in control and bestrophin siRNA-treated cells.
Measurements were performed under basal conditions (T40), in the
presence of 10 lM forskolin (T50 and T60) and 50 lM DIDS (T70 and
T80). Net ﬂuxes were obtained from six experiments. P < 0:05, ﬂuxes
in control and siRNA-treated cells. #P < 0:01, eﬀect of DIDS under
control conditions.
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T60). Subsequent application of DIDS (50 lM, basolateral)
decreased JAB from 2.92 0.30 to 1.30 0.46 lEq cm2 h1
(P < 0:05) under control conditions, but had no signiﬁcant
eﬀect on 36Cl ﬂux in siRNA treated cells (Table 1, T70
and T80).Table 1
Unidirectional and net ion ﬂuxes across short-circuited Calu-3 monolayers
Sample Treatment Control
JBA JAB JNET
T40 Baseline 0.98 0.21 1.11 0.11 )0.13
T50 Forskolin 3.57 0.60 2.40 0.23 1.17
T60 Forskolin 2.67 0.23 2.92 0.30 )0.26
T70 +DIDS 2.51 0.44 1.30 0.46 1.21
T80 +DIDS 2.31 0.31 1.33 0.14 0.98
Flux values are in lEq cm2 h1. Forskolin (10 lM) was added bilaterally,
obtained from n ¼ 3 experiments, therefore net ﬂuxes from n ¼ 6 experimen
* P < 0:05, signiﬁcantly diﬀerent from the corresponding ﬂux in control cells4. Discussion
Since its discovery in Caenorhabditis elegans [23], RNA in-
terference has become an eﬀective method for the analysis of
gene function [24]. We used this technique to study the bes-
trophin gene–function relationship in human airway epithelial
cells. Our results suggest that bestrophin functions as a baso-
lateral Cl channel regulated via cAMP- and cGMP-depen-
dent phosphorylation.
Current models of bestrophin topology suggest that this
protein consists of either four [10,25] or six [16,17] trans-
membrane spanning a-helices and a large C-terminal cyto-
plasmic region, containing four potential phosphorylation sites
for protein kinase A, two for protein kinase C, and three for
cGMP-dependent protein kinase (PKG) [26]. In earlier studies,
we had shown that GSNO stimulates transepithelial anion
secretion acting via a cGMP-dependent pathway [20]. More
recently, basolateral Cl channels were shown to be activated
via cAMP-dependent phosphorylation [9]. The results of this
study show that silencing the bestrophin gene with siRNA
decreases GSNO-activated, DIDS-sensitive Isc, and forskolin-
activated 36Cl ﬂux. This suggests that bestrophin functions as
a basolateral Cl channel regulated via cAMP- or cGMP-de-
pendent phosphorylation. There is also the possibility of cross
talk between cAMP- and cGMP-dependent pathways because
cAMP inhibits cGMP-speciﬁc phosphodiesterase 5, and both
cAMP and cGMP can activate PKG [27]. Bestrophin is known
to interact with protein phosphatase 2A [28] and phosphory-
lation/dephosphorylation of its C-terminal could act as the on/
oﬀ switch regulating channel activity.Bestrophin siRNA-treated
JBA JAB JNET
 0.18 1.41 0.23 0.95 0.08 0.46 0.09
 0.32 4.46 0.38 2.48 0.23 1.97 0.19
 0.19 3.18 0.31 2.16 0.40 1.02 0.16
 0.32 3.28 0.23 2.25 0.32 1.03 0.26
 0.17 2.80 0.26 1.81 0.33 0.98 0.21
DIDS (50 lM) was added basolaterally. Each unidirectional ﬂux was
ts.
.
554 V. Duta et al. / FEBS Letters 577 (2004) 551–554Western blot experiments suggest that siRNA treatment
reduces bestrophin expression in Calu-3 cells by 65%.
However, measurements of 36Cl ﬂux indicate that bestrophin
siRNA reduces basal JBA by only 14%. This suggests that
bestrophin may not be the only Cl channel present in the
basolateral membrane. There is signiﬁcant evidence that
ubiquitously expressed ClC-2 Cl channels are present in the
basolateral membrane of epithelial cells [6–8,29] and these
channels could also contribute to the basolateral Cl con-
ductance.
Although bestrophins were initially shown to function as the
Cl channels in RPE cells [15,16], there is now signiﬁcant ev-
idence to suggest that these channels could also play an im-
portant physiological role in other tissues. Boese et al. [30]
have shown that Cl conductances in collecting duct cells have
some important similarities to bestrophin-induced conduc-
tances [30]. Others have described cGMP-activated Cl chan-
nels in smooth muscle cells that share some characteristics with
the bestrophin channel family [31,32]. Interestingly, recent
studies with a member of the CLCA channel family, pCLCA1,
have found that although the CLCA protein localized to the
basal RPE, its primary function was to regulate the activity of
other proteins rather than to mediate Cl conductance [33].
Although the results of our study strongly suggest that bes-
trophin functions as a basolateral Cl channel, we cannot
exclude the possibility that this protein may function as a
regulatory component of an ion channel-protein complex.
However, recent experiments showing that mutations of bes-
trophin residues in a putative channel pore alter the relative
permeability and conductance for diﬀerent anions [17] provide
strong evidence that bestrophins function as ion channels,
rather than regulators of channel activity.
In conclusion, the results of our studies show, for the ﬁrst
time, that bestrophin is present in airway epithelial cells and
functions as a basolateral Cl channel. We also show that
bestrophin channel activity in Calu-3 cells is regulated via
cAMP- and cGMP-dependent pathways. Basolateral Cl
channels have previously been proposed to play a crucial role
in determining the magnitude of Cl and HCO3 secretion [9],
and the knowledge of their molecular identity may have im-
portant clinical implications.
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